Galecto, Inc. (GLTO)
| Previous Close | 0.7096 |
| Open | 0.6920 |
| Bid | 0.6397 x 100 |
| Ask | 0.7153 x 100 |
| Day's Range | 0.6751 - 0.7150 |
| 52 Week Range | 0.5000 - 3.7000 |
| Volume | |
| Avg. Volume | 200,771 |
| Market Cap | 18.982M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1000 |
| Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
GlobeNewswireGalecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinomaBOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for ca
ZacksGalecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksWhat Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
